Compare Boston Scientific Corporation (BSX) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs UnitedHealth Group Inc — how do they compare? Boston Scientific Corporation trades at $43.29 (market cap $66.37B), while UnitedHealth Group Inc trades at $420.44 (market cap $389.68B). The key difference: UnitedHealth Group Inc is far larger — about 5.9× Boston Scientific Corporation's market cap, and UnitedHealth Group Inc pays a 2.16% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | UNH | |
|---|---|---|
Market Cap | $66.37B | $389.68B |
Sector | Health | Health |
52-Week High | $108.14 | $431.68 |
52-Week Low | $42.63 | $237.77 |
Enterprise Value | $75.94B | $436.36B |
Dividend Yield | — | 2.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
UnitedHealth Group (UNH) trades at $429.09, up 1.05% on the day, with a bullish technical outlook and strong analyst consensus. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.23 exceeding expectations, and a dividend of $2.32 payable in June 2026. Revenue growth remains robust, reaching $447.57B in 2025, though net margins have compressed to 2.68%.
Outlook is positive due to aging demographics and tech innovation in healthcare, but risks include regulatory scrutiny and margin pressure. Wall Street's average price target of $438.33 suggests modest upside, supported by 82.69% buy ratings. Investors should weigh solid cash flow generation against legal challenges and rising debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
